Columbus Venture Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, founded in 2015. The company focuses on developing therapeutic drugs aimed at enhancing the effectiveness of anti-cancer therapies. Its lead product, LUT014, is a proprietary small molecule B-Raf inhibitor designed to facilitate the administration of epidermal growth factor receptor (EGFR) inhibitors. This innovative approach helps mitigate the common cutaneous side effects associated with EGFR treatments, thereby improving the overall quality of life for patients undergoing cancer therapy.

Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Curve Therapeutics Limited is a drug-discovery company based in London, United Kingdom, founded in 2019. The company focuses on developing technologies to target currently undruggable disease-modifying targets, with a primary emphasis on cancer. Curve has created an innovative screening platform that allows for the functional screening of genetically encoded Microcycle™ libraries against a variety of disease-associated targets in their native conformation within mammalian cells. This platform is designed to facilitate the discovery of first-in-class therapeutics, enabling the development of a pipeline of novel cancer drugs. By targeting challenging cancer interactions, including intracellular protein-protein and protein-gene interactions, Curve Therapeutics aims to deliver advanced treatments for complex cancer-related conditions.

Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Highlight Therapeutics is a private, clinical-stage company focused on developing RNA-based immuno-oncology therapies aimed at treating cancer. The company's innovative therapies mimic the effects of viral infections to enhance the therapeutic impact of existing drugs. This approach allows medical professionals to promote quicker tumor recovery in patients, thereby unlocking the potential of immuno-oncology in cancer treatment.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.